on FERMENTALG (EPA:FALG)
Fermentalg: Growth and Improvements in 2024
Fermentalg, a specialist in aquatic bio-solutions, announces positive results for 2024. Revenue nearly tripled to €11.5 million thanks to a solid commercial strategy and a key partnership with Huvepharma. Huvepharma, now a shareholder in Fermentalg, ensures a unique European production of algae-based omega-3s.
The company made progress on several fronts, including entering new markets, especially infant nutrition, and awaiting FDA approval for a natural blue colorant. Manufacturing efficiency also increased, improving profitability despite a slight increase in expenses.
Fermentalg has a strengthened financial position with cash of €20.6 million and reduced debt through bond conversions. With solid economic performance and expected expansion, the company is targeting revenue of €25 million by 2026.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all FERMENTALG news